دورية أكاديمية
68 Ga-EMP-100 PET/CT-a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma-first in-human biodistribution and imaging results.
| العنوان: | 68 Ga-EMP-100 PET/CT-a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma-first in-human biodistribution and imaging results. |
|---|---|
| المؤلفون: | Mittlmeier LM; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. Lena.Mittlmeier@med.uni-muenchen.de.; Department of Urology, University Hospital, LMU Munich, Munich, Germany. Lena.Mittlmeier@med.uni-muenchen.de., Todica A; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany., Gildehaus FJ; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany., Unterrainer M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Beyer L; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany., Brendel M; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany., Albert NL; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany., Ledderose ST; Institute of Pathology, LMU Munich, Munich, Germany., Vettermann FJ; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany., Schott M; Department of Urology, University Hospital, LMU Munich, Munich, Germany., Rodler S; Department of Urology, University Hospital, LMU Munich, Munich, Germany., Marcon J; Department of Urology, University Hospital, LMU Munich, Munich, Germany., Ilhan H; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany., Cyran CC; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Stief CG; Department of Urology, University Hospital, LMU Munich, Munich, Germany., Staehler M; Department of Urology, University Hospital, LMU Munich, Munich, Germany., Bartenstein P; Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. |
| المصدر: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2022 Apr; Vol. 49 (5), pp. 1711-1720. Date of Electronic Publication: 2021 Oct 28. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer-Verlag Berlin, 2002- |
| مواضيع طبية MeSH: | Carcinoma, Renal Cell*/diagnostic imaging , Kidney Neoplasms*/diagnostic imaging, Gallium Radioisotopes ; Humans ; Ligands ; Positron Emission Tomography Computed Tomography/methods ; Tissue Distribution |
| مستخلص: | Background: 68 Ga-EMP-100 is a novel positron emission tomography (PET) ligand that directly targets tumoral c-MET expression. Upregulation of the receptor tyrosin kinase c-MET in renal cell carcinoma (RCC) is correlated with overall survival in metastatic disease (mRCC). Clinicopathological staging of c-MET expression could improve patient management prior to systemic therapy with for instance inhibitors targeting c-MET such as cabozantinib. We present the first in-human data of 68 Ga-EMP-100 in mRCC patients evaluating uptake characteristics in metastases and primary RCC. Methods: Twelve patients with mRCC prior to anticipated cabozantinib therapy underwent 68 Ga-EMP-100 PET/CT imaging. We compared the biodistribution in normal organs and tumor uptake of mRCC lesions by standard uptake value (SUV Results: Overall, 87 tumor lesions were analyzed. Of these, 68/87 (79.3%) were visually rated c-MET-positive comprising a median SUV Conclusion: Targeting c-MET expression, 68 Ga-EMP-100 shows distinctly elevated uptake in mRCC patients with partially high inter- and intra-individual differences comprising both c-MET-positive and c-MET-negative lesions. Our first clinical results warrant further systemic studies investigating the clinical use of 68 Ga-EMP-100 as a biomarker in mRCC patients. (© 2021. The Author(s).) |
| References: | Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–23. (PMID: 10.1056/NEJMoa1510016) Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27. (PMID: 10.1016/S1470-2045(16)30107-3) Choueiri TK, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. (PMID: 10.1056/NEJMoa2026982) Hsieh JJ, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):1–19. (PMID: 10.1038/nrdp.2017.9) Ljungberg B, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21. (PMID: 10.1016/j.eururo.2011.06.049) Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep. 2013;15(2):76–82. (PMID: 10.1007/s11912-012-0289-x) Bellon SF, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008;283(5):2675–83. (PMID: 10.1074/jbc.M705774200) Gibney G, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343–9. (PMID: 10.1093/annonc/mds463) Macher-Goeppinger S, et al. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget. 2017;8(1):1046. (PMID: 10.18632/oncotarget.13540) Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res. 2006;12(16):4876–81. (PMID: 10.1158/1078-0432.CCR-06-0362) Kim JH, Kim BJ, Kim HS. Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget. 2017;8(43):75478–87. (PMID: 10.18632/oncotarget.20796) Bedke J, et al. Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. Eur Urol. 2021;79(3):339–42. (PMID: 10.1016/j.eururo.2020.12.005) D’Angelo A, et al. An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). Crit Rev Oncol Hematol. 2020;149:102921. (PMID: 10.1016/j.critrevonc.2020.102921) Ljungberg B, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. (PMID: 10.1016/j.eururo.2019.02.011) Pozzessere C, et al. Renal cell carcinoma: the oncologist asks, can PSMA PET/CT answer? Curr Urol Rep. 2019;20(11):68. (PMID: 10.1007/s11934-019-0938-9) Fendler WP, et al. 68 Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24. (PMID: 10.1007/s00259-017-3670-z) Pozzessere C, et al. Renal cell carcinoma: the oncologist asks, can PSMA PET/CT answer? Curr Urol Rep. 2019;20(11):1–10. (PMID: 10.1007/s11934-019-0938-9) Ahn T, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imag Biol. 2019;21(5):799–807. (PMID: 10.1007/s11307-018-01307-0) Rowe SP, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18 F-DCFPyL PET/CT. Ann Nucl Med. 2015;29(10):877–82. (PMID: 10.1007/s12149-015-1017-z) Peter L, et al. Molecular imaging of late somatostatin receptor–positive metastases of renal cell carcinoma in the pancreas by 68 Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clin Nucl Med. 2014;39(8):713–6. (PMID: 10.1097/RLU.0000000000000351) Vamadevan S, et al. 68 Ga-DOTATATE uptake in a soft tissue metastasis from clear cell renal cell cancer. Clin Nucl Med. 2018;43(1):44–5. (PMID: 10.1097/RLU.0000000000001887) Buckle T, et al. Translation of c-Met targeted image-guided surgery solutions in oral cavity cancer—initial proof of concept data. Cancers. 2021;13(11):2674. (PMID: 10.3390/cancers13112674) Burggraaf J, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015;21(8):955–61. (PMID: 10.1038/nm.3641) de Vries HM, Bekers E, van Oosterom MN, Krakullukcu MB, van der Poel HG, van Leeuwen FW, et al. c-MET receptor-targeted fluorescence on the road to image-guided surgery in penile squamous cell carcinoma patients. J Nucl Med. 2021. Assembly, W.M.A.G., World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2004; 15(1): 124–9. d’Amico A, et al. Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography/computed tomography on urine radioactivity and detection of uterine cervical cancer. Nuclear Medicine Review. 2014;17(2):83–6. (PMID: 10.5603/NMR.2014.0022) Sheth S, et al. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. Radiographics. 2001;21(suppl_1):S237–54. (PMID: 10.1148/radiographics.21.suppl_1.g01oc18s237) Kabasakal EDL, Kanmaz MHB. 68 Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2. (PMID: 10.1007/s00259-014-2766-y) Nakamoto Y, et al. Clinical utility of 68 Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46(7):1524–30. (PMID: 10.1007/s00259-019-04298-4) Sawicki LM, et al. Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared with 18F-FDG PET/CT in patients with known malignancies. J Nucl Med. 2016;57(1):15–20. (PMID: 10.2967/jnumed.115.162966) Volpe A, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007;178(2):379–86. (PMID: 10.1016/j.juro.2007.03.131) Busch J, et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011;11(1):1–5. (PMID: 10.1186/1471-2407-11-295) Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308. (PMID: 10.1158/1535-7163.MCT-11-0264) Sierra JR, Tsao M-S. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1_suppl):S21–35. (PMID: 10.1177/1758834011422557) |
| فهرسة مساهمة: | Keywords: Metastatic renal cell carcinoma; PET/CT imaging; Receptor tyrosin kinase; Receptor tyrosin kinase inhibitors; c-MET |
| المشرفين على المادة: | 0 (Gallium Radioisotopes) 0 (Ligands) |
| تواريخ الأحداث: | Date Created: 20211028 Date Completed: 20220411 Latest Revision: 20220518 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC8940803 |
| DOI: | 10.1007/s00259-021-05596-6 |
| PMID: | 34708249 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1619-7089 |
|---|---|
| DOI: | 10.1007/s00259-021-05596-6 |